NewMed, Kim Ho-chul, new CEO, spurred global advancement
Sep 12, 2024
|
CEO Kim Ho-chul is a professor at Kyung Hee University's School of Oriental Medicine and has served as an exchange professor at Cornell Medical School in the United States, Johns Hopkins Medical School, Chinese Capital Medical School, and Vietnamese Traditional Medicine University. It has achieved outstanding achievements in the field of oriental medicine and natural product research, and has attracted attention from the industry for contributing to the development of products of global brands such as the consonants of AmorePacific Sulwhasoo and the prescription of L'Oreal.
CEO Kim established NewMed within Kyung Hee University's Business Incubation Center in 2003 and served as CEO until 2011 to lay the foundation for NewMed. After that, he returned to the academic world and focused on fostering and researching and developing disciples, but this time, he returned as CEO again to make NewMed's global leap forward. CEO Kim Ho-chul has been deeply involved in research and management since the beginning of NewMed's foundation, and has suggested directions for the company to play a leading role in natural product research and development.
NewMed is a natural product research and development company with a variety of individually recognized raw materials, including Hwanggi extract (HT042), the first and only key growth functional raw material in Korea, and has know-how in researching and developing all processes from cultivation to industrialization. In addition, it has several individually recognized raw materials such as oriental raisin fruit extract powder (HP426, liver health), peony extract (HT074, stomach health), and spiny obonji (HT008, joint health).
CEO Kim Ho-chul plans to further accelerate NewMed's global expansion. NewMed is growing natural products directly near Baekdusan Mountain and is considering establishing an overseas factory based on its own technology. "We will further strengthen NewMed's research capabilities and strive to ensure that Korea's natural product research and products are recognized in the global market," Kim said. "We will supply stable and innovative products to the global market through a system that directly manages all processes from cultivation to industrialization." NewMed has currently selected Korea Investment & Securities as its host and has begun preparing for an IPO in earnest.
A NewMed official said, `The inauguration of CEO Kim Ho-chul is an important turning point for NewMed to become a leading company in natural product research and development in the global market beyond Korea,' adding, `We plan to accelerate the commercialization of functional raw materials for natural products through R&D and strengthen cooperation with overseas partners to secure competitiveness in the global healthcare market.'
compact@sportschosun.com
